As of today (2024-06-17), YSB's share price is HK$8.61.
YSB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3.06. Hence, YSB's Price-to-Free-Cash-Flow Ratio for today is 2.82.
The historical rank and industry rank for YSB's Price-to-Free-Cash-Flow or its related term are showing as below:
HKSE:09885'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.77 Med: 85.83 Max: 646.88
Current: 2.81
During the past 4 years, YSB's highest Price-to-Free-Cash-Flow Ratio was 646.88. The lowest was 2.77. And the median was 85.83.
HKSE:09885's Price-to-Free-Cash-Flow is ranked better than 94.69% of 358
companies
in the Healthcare Providers & Services industry
Industry Median: 16.675
vs HKSE:09885: 2.81
During the past 12 months, the average Free Cash Flow per Share Growth Rate of YSB was 1179.20% per year.
YSB Price-to-Free-Cash-Flow Historical Data
The historical data trend for YSB's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of YSB's Price-to-Free-Cash-Flow
For the Pharmaceutical Retailers subindustry, YSB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YSB's Price-to-Free-Cash-Flow Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, YSB's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where YSB's Price-to-Free-Cash-Flow falls into.
YSB Price-to-Free-Cash-Flow Calculation
YSB's Price-to-Free-Cash-Flow ratio for today is calculated as
YSB's Share Price of today is HK$8.61.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. YSB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
YSB Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of YSB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The Company is committed to using digitalization to empower participants in the out-of-hospital pharmaceutical market, including pharmaceutical companies, distributors, vendors, pharmacies and primary healthcare institutions, and strives to bring pharmaceutical health products and services to the downstream safely and efficiently, so that users can easily obtain a large number of comprehensive and high-quality drugs at a fair and transparent price. It has turned the process of pharmaceutical transaction and service into a digitalized, standardized and scalable one.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09885 has been successfully added to your